TGFB1 and bronchopulmonary dysplasia: Nebulized PPARγ agonists may represent a potential strategy for improving postnatal lung maturation, both by inhibition of the TGF-β/WNT/β-catenin pathway and by preventing neonatal hyperoxia-induced lung injury in premature BPD infants, thereby reducing morbidity and mortality.